Skip to main content
upsher smith exterior hero

Upsher-Smith opens manufacturing facility in Minnesota

Upsher-Smith is now offering contract manufacturing, packaging and serialization capabilities.

Upsher-Smith has opened its new, 270,000-sq.-ft., state-of-the-art greenfield manufacturing facility. The Maple Grove, Minn., facility offers fully up-to-date packaging and serialization capabilities and supports contract manufacturing for third parties.  

“Upsher-Smith will draw upon its long-standing, award-winning relationships with distributors and demonstrated track record in several key areas such as Food and Drug Administration compliance and inspection history, environmental health and safety performance and superior customer service. The company’s prime geographical location and outstanding history of quality allow Upsher-Smith to offer controlled costs and award-winning levels of customer support,” the company said.

[Read more: Upsher-Smith extends fluoxetine product line]

“Upsher-Smith is a trusted partner in health with a 104-year history of manufacturing excellence,” said Rich Fisher, president and chief operating officer of Upsher-Smith. “The opening of this world-class facility marks another important milestone for our company. We plan to use this innovative asset to support our own organic production and pipeline as well as partners looking for end-to-end supply chain solutions in the contract manufacturing space.”     

The company’s offerings include environmentally sustainable solvent and aqueous-based oral solid dosage manufacturing in tablet or capsule form, powders, liquids and suspensions, as well as serialized packaging solutions including OSD/liquid bottles, unit dose blisters and liquid cups and powder filling in sachets, bottles and cans.

Outbound packaging configurations also are aggregated in accordance with the pending Drug Supply Chain Security Act conformance standards, the company noted.

[Read more: Upsher-Smith extends generic Haldol line]

In addition to Upsher-Smith’s new facility, the company manufactures small, commercial batches of products destined for FDA submissions and clinical purposes in a nearby Pilot Plant, known as Plant B.

This ad will auto-close in 10 seconds